ES2392310T3 - Uso de extractos o sustancias extractivas de Piper Cubeba L. como componentes activos en un medicamento para el tratamiento de enfermedades cancerosas - Google Patents
Uso de extractos o sustancias extractivas de Piper Cubeba L. como componentes activos en un medicamento para el tratamiento de enfermedades cancerosas Download PDFInfo
- Publication number
- ES2392310T3 ES2392310T3 ES08783450T ES08783450T ES2392310T3 ES 2392310 T3 ES2392310 T3 ES 2392310T3 ES 08783450 T ES08783450 T ES 08783450T ES 08783450 T ES08783450 T ES 08783450T ES 2392310 T3 ES2392310 T3 ES 2392310T3
- Authority
- ES
- Spain
- Prior art keywords
- extract
- alcohol
- stage
- fruits
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 129
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 239000001086 piper cubeba l. Substances 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 239000000126 substance Substances 0.000 title description 34
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000341 volatile oil Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 238000001256 steam distillation Methods 0.000 claims abstract description 4
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 230000002280 anti-androgenic effect Effects 0.000 claims description 9
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 8
- 229960003473 androstanolone Drugs 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 7
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 6
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XUEHVOLRMXNRKQ-KHMAMNHCSA-N alpha-cubebene Chemical compound CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1C(C)=CC3 XUEHVOLRMXNRKQ-KHMAMNHCSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 43
- DIYWRNLYKJKHAM-MDOVXXIYSA-N (-)-cubebin Chemical compound C1=C2OCOC2=CC(C[C@@H]2[C@@H](CC=3C=C4OCOC4=CC=3)CO[C@@H]2O)=C1 DIYWRNLYKJKHAM-MDOVXXIYSA-N 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 16
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 14
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 230000006820 DNA synthesis Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 108010080146 androgen receptors Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 102000001307 androgen receptors Human genes 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940123934 Reductase inhibitor Drugs 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 240000003731 Piper cubeba Species 0.000 description 1
- 235000002711 Piper cubeba Nutrition 0.000 description 1
- 241000949456 Zanthoxylum Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012432 gingerbread Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 244000077696 naranjillo Species 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01289/07A CH698627B1 (de) | 2007-08-16 | 2007-08-16 | Herstellung und Verwendung von Extrakten oder Extraktivstoffen aus Piper cubeba L. als wirksame Bestandteile in einem Medikament zur Behandlung von Krebserkrankungen. |
| CH12892007 | 2007-08-16 | ||
| PCT/CH2008/000350 WO2009021347A1 (de) | 2007-08-16 | 2008-08-15 | Verwendung von extrakten oder extraktivstoffen aus piper cubeba l. als wirksame bestandteile in einem medikament zur behandlung von krebserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2392310T3 true ES2392310T3 (es) | 2012-12-07 |
Family
ID=38668948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08783450T Active ES2392310T3 (es) | 2007-08-16 | 2008-08-15 | Uso de extractos o sustancias extractivas de Piper Cubeba L. como componentes activos en un medicamento para el tratamiento de enfermedades cancerosas |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8404286B2 (enExample) |
| EP (1) | EP2182966B1 (enExample) |
| JP (1) | JP5378379B2 (enExample) |
| KR (1) | KR20100089815A (enExample) |
| CN (1) | CN102065875B (enExample) |
| AU (1) | AU2008286636B2 (enExample) |
| BR (1) | BRPI0815188A2 (enExample) |
| CA (1) | CA2696499A1 (enExample) |
| CH (1) | CH698627B1 (enExample) |
| ES (1) | ES2392310T3 (enExample) |
| PL (1) | PL2182966T3 (enExample) |
| RU (1) | RU2470657C2 (enExample) |
| WO (1) | WO2009021347A1 (enExample) |
| ZA (1) | ZA201000959B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472333B (zh) * | 2008-06-26 | 2015-02-11 | Piramal Entpr Ltd | 治療口腔念珠菌病之口服草本組成物 |
| JP5806231B2 (ja) * | 2009-12-21 | 2015-11-10 | アセフ エス．アー． | 勃起障害の治療における血管拡張剤としてのクベビン、ジベンジルブチルロラクトリンリグナン、その半合成誘導体および合成誘導体、ならびに他のリグナンおよびネオリグナン |
| WO2014027857A1 (ko) * | 2012-08-16 | 2014-02-20 | 부산대학교 산학협력단 | 알파-이소-쿠베벤 또는 알파-이소-쿠베베놀을 유효성분으로 포함하는 감염성 및 염증성 질환의 예방 또는 치료용 조성물 |
| WO2014086379A1 (en) | 2012-12-03 | 2014-06-12 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag | Lignan compositions |
| FR3085846B1 (fr) * | 2018-09-13 | 2022-01-21 | Robertet Sa | Utilisation d’extrait de p.nigrum, p. cubeba et/ou s. therebentifolius dans des preparations cosmetiques pour favoriser la pousse des poils |
| JP7197908B2 (ja) * | 2019-03-04 | 2022-12-28 | 株式会社ナチュファルマ琉球 | 骨減少性疾患の予防及び／又は治療用組成物 |
| CN114574286B (zh) * | 2022-02-18 | 2024-03-22 | 中国热带农业科学院香料饮料研究所 | 一种具有抗炎活性的胡椒精油及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815177D0 (en) * | 1998-07-13 | 1998-09-09 | King S College London | Treatment of skin disorders |
| JP3091962B2 (ja) * | 1998-09-25 | 2000-09-25 | アルプス薬品工業株式会社 | テストステロン−５α−レダクターゼ阻害剤 |
| WO2003047551A1 (en) * | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| BR0201237A (pt) | 2002-03-25 | 2003-12-02 | Fundacao De Amparo A Pesquisa | Processo de obtenção de lignanas dibenzilbutirolactÈnicas, processo de obtenção de derivados sintéticos de lignanas ostentando atividades quimioprofilática e terapêutica antichagásica |
| US20030228383A1 (en) * | 2002-06-06 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals, Ltd. | Herbal cough formulations and process for the preparation thereof |
| JP2004160165A (ja) * | 2002-09-17 | 2004-06-10 | Pauretsuku:Kk | 生薬成分製剤の造粒方法 |
| EP1581237B1 (en) * | 2002-12-30 | 2007-06-27 | Council of Scientific and Industrial Research | Development of an anti-cough, anti-tussive and throat soothing herbal formulation |
| JP4319417B2 (ja) * | 2003-01-30 | 2009-08-26 | 学校法人近畿大学 | メラニン産生不全症治療剤 |
| US20070248693A1 (en) * | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
-
2007
- 2007-08-16 CH CH01289/07A patent/CH698627B1/de not_active IP Right Cessation
-
2008
- 2008-08-15 JP JP2010520393A patent/JP5378379B2/ja not_active Expired - Fee Related
- 2008-08-15 CN CN200880111798XA patent/CN102065875B/zh not_active Expired - Fee Related
- 2008-08-15 PL PL08783450T patent/PL2182966T3/pl unknown
- 2008-08-15 AU AU2008286636A patent/AU2008286636B2/en not_active Ceased
- 2008-08-15 WO PCT/CH2008/000350 patent/WO2009021347A1/de not_active Ceased
- 2008-08-15 CA CA2696499A patent/CA2696499A1/en not_active Abandoned
- 2008-08-15 US US12/673,656 patent/US8404286B2/en not_active Expired - Fee Related
- 2008-08-15 ES ES08783450T patent/ES2392310T3/es active Active
- 2008-08-15 KR KR1020107005684A patent/KR20100089815A/ko not_active Ceased
- 2008-08-15 RU RU2010109750/15A patent/RU2470657C2/ru not_active IP Right Cessation
- 2008-08-15 BR BRPI0815188 patent/BRPI0815188A2/pt not_active IP Right Cessation
- 2008-08-15 EP EP08783450A patent/EP2182966B1/de active Active
-
2010
- 2010-02-10 ZA ZA201000959A patent/ZA201000959B/xx unknown
-
2013
- 2013-02-28 US US13/780,129 patent/US9248156B2/en not_active Expired - Fee Related
-
2016
- 2016-02-02 US US15/013,654 patent/US20160193272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100089815A (ko) | 2010-08-12 |
| EP2182966B1 (de) | 2012-08-08 |
| AU2008286636A1 (en) | 2009-02-19 |
| RU2470657C2 (ru) | 2012-12-27 |
| WO2009021347A1 (de) | 2009-02-19 |
| AU2008286636B2 (en) | 2013-10-24 |
| US20110135760A1 (en) | 2011-06-09 |
| JP5378379B2 (ja) | 2013-12-25 |
| CH698627B1 (de) | 2009-09-15 |
| ZA201000959B (en) | 2010-10-27 |
| CN102065875B (zh) | 2013-07-17 |
| RU2010109750A (ru) | 2011-09-27 |
| US9248156B2 (en) | 2016-02-02 |
| BRPI0815188A2 (pt) | 2015-03-31 |
| US20160193272A1 (en) | 2016-07-07 |
| CN102065875A (zh) | 2011-05-18 |
| PL2182966T3 (pl) | 2013-01-31 |
| CA2696499A1 (en) | 2009-02-19 |
| US20130251826A1 (en) | 2013-09-26 |
| US8404286B2 (en) | 2013-03-26 |
| JP2010536718A (ja) | 2010-12-02 |
| EP2182966A1 (de) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2392310T3 (es) | Uso de extractos o sustancias extractivas de Piper Cubeba L. como componentes activos en un medicamento para el tratamiento de enfermedades cancerosas | |
| EP2544682B1 (en) | Phytocannabinoids in the treatment of cancer | |
| Verma et al. | Study of Convolvulus pluricaulis for antioxidant and anticonvulsant activity | |
| ES2845680T3 (es) | Composición que contiene un extracto de Echinacea y derivados de ácido linoleico | |
| Chai et al. | Antioxidant properties of aqueous extracts of Selaginella willdenowii | |
| Giacomelli et al. | New insights into the anticancer activity of carnosol: p53 reactivation in the U87MG human glioblastoma cell line | |
| JP5221128B2 (ja) | センシンレン（Ａｎｄｒｏｇｒａｐｈｉｓｐａｎｉｃｕｌａｔａ）由来の粗抽出物 | |
| US20220000964A1 (en) | Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis | |
| CN115515614B (zh) | 用于改进关节健康和治疗关节炎的包含山姜属和其它植物提取物的组合物 | |
| Cai et al. | Chemical constituents of volatile oil from Pyrolae herba and antiproliferative activity against SW1353 human chondrosarcoma cells | |
| Lu et al. | A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest | |
| Lee et al. | SJSZ glycoprotein (38ákDa) prevents thymus atrophy and enhances expression of IL-2 and IL-12 in diethylnitrosamine-induced hepatocarcinogenesis | |
| Salem et al. | ANTI-CANCER ACTIVITY OF GRAVIOLA (Annona muricata) LEAVES EXTRACT ON INDUCED BREAST CANCER IN RATS’MODEL. | |
| BR112019018744A2 (pt) | uso de oleorresina de copaifera em patologias da próstata | |
| Ibrahim et al. | Effect of Salvia triloba L. f. extracts on neoplastic cell lines | |
| US10188689B2 (en) | Method and composition for treating breast cancer | |
| KR102501845B1 (ko) | 백수오 추출물을 유효성분으로 포함하는 피부 재생 또는 상처 치료용 조성물 | |
| KR20110076718A (ko) | 등골나물 추출물을 포함하는 항염증제 | |
| Kale et al. | Benzyl Benzoate Isolation from Acridocarpus smeathmannii (DC.) Roots and Its Bioactivity on Human Prostate Smooth Muscle Contractions | |
| Sithole | Immunomodulatory and Anticancer Potential of a Traditional Medicine Product from a Traditional Healer Against MCF-7 Breast Cancer Cells | |
| Altabbal | ROLE OF AUTOPHAGY IN ACRIDOCARPUS ORIENTALIS-INDUCED ANTI-BREAST CANCER ACTIVITY | |
| KR20120084139A (ko) | 호로파 추출물을 포함하는 뇌암 치료용 조성물 및 미백 기능성 화장품 | |
| Bnouham | Recent advances in pharmacologic study of anticancer natural products from medicinal plants in Morocco | |
| Singh | Anti Cancer Activity of Ethanolic Extract of Withania somnifera against T-24 Urinary Bladder Cell Line, Hela—Cervical Adeno Carcinoma and AGS—Human Adeno Gastric Carcinoma Cell Lines | |
| Arulmozhi et al. | Investigation of anti-arthritic, antioxidant properties of dichloromethane fraction of Alstonia scholaris Linn. in Freund’s complete adjuvant induced rats and identification of biomarker |